🇺🇸 FDA
Pipeline program

GLASDEGIB , DAUNORUBICIN , AZACITIDINE , AMSACRINE , CYTARABINE , DECITABINE , FLUDARABINE , ETOPOSIDE , GILTERITINIB, IDARUBICIN , VENETOCLAX , MITOXANTRONE , IVOSIDENIB , CYTARABINE , CLADRIBINE , GEMTUZUMAB OZOGAMICIN

IRST204.07

Phase 3 small_molecule active

Quick answer

GLASDEGIB , DAUNORUBICIN , AZACITIDINE , AMSACRINE , CYTARABINE , DECITABINE , FLUDARABINE , ETOPOSIDE , GILTERITINIB, IDARUBICIN , VENETOCLAX , MITOXANTRONE , IVOSIDENIB , CYTARABINE , CLADRIBINE , GEMTUZUMAB OZOGAMICIN for Acute myeloid leukemia is a Phase 3 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).

Program details

Company
Istituto Gentili S.r.l.
Indication
Acute myeloid leukemia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials